Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

New CEO to Promedvi

Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.

EUR 2 million for peanut allergies

ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.

Vitamin D is mental health aid

Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.

Dako appoints new CEO

The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.

Dupont gets new business manager

The Swedish API manufacturer Dupont Chemoswed has appointed a new business development manager.

Swedish Medtech söker ekonom/jurist

LEO Pharma - International Clinical Trial Manager

Medicult disclaims Swedish offer

The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.

Pronova Biopharma grows

Recently, Norway's Pronova Biopharma announced the creation of new jobs in Denmark

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

Medicult acquires embryo scanner

The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.

Sales Representative, Applied Biosystems

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.